Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Other cookies are those that are being identified and have not been classified into any category as yet.

No cookies to display.

On Demand Virtual R&D Event Replay:
“Rectifying Protein Dysfunction: RTY-694 for the Treatment of Primary Sclerosing Cholangitis”

Jodie Morrison

Chief Executive Officer, Q32 Bio

Jodie Morrison is an accomplished executive and board member with experience from start up through mid-size public biotech and pharmaceutical companies. She currently serves as CEO of Q32 Bio (QTTB), a publicly traded clinical stage biotech company, which she joined from her role as a Venture Partner at the founding investor Atlas Venture. Her prior operating roles include CEO of Cadent Therapeutics (acquired by Novartis in 2021), CEO at Keryx Biopharmaceuticals, Inc. (successful public/public MOE with Akebia Therapeutics), COO at Syntimmune, CEO of eGenesis and CEO of Tokai Pharmaceuticals, Inc. Other prior roles include COO and VP/Head of Clinical and Program Operations at Tokai and various roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc. Ms. Morrison currently serves as a board member at Verve (VERV). She previously held public board roles at Aileron (ALRN), Ribon (private, chairman), Keryx (KERX), prior to CEO role, Akebia (AKBA) and Novus (NVUS). She also serves as a board member at Life Science Cares and on the key advisory board for Harvard Business School’s Blavatnik Fellowship in Life Science Entrepreneurship. Jodie has been awarded the Boston Business Journal’s “Power 50” and “Women to Watch” awards and WEST’s “Making a Difference” award. Ms. Morrison received her business training through the GBEP program at the MIT Sloan School of Management, her clinical research certification from Boston University School of Medicine and her B.A. in neuroscience from Mount Holyoke College.